期刊文献+

索拉非尼对敏感人肝癌细胞株MAPK信号通路基因表达的影响 被引量:3

Gene expression profile of MAPK signal pathway in a human hepatocellular carcinoma cell line sensitive to sorafenib
下载PDF
导出
摘要 目的:筛选对索拉非尼敏感的人肝癌细胞株,检测索拉非尼作用于敏感细胞株后MAPK信号通路基因表达谱的变化。方法:索拉非尼作用于人肝癌细胞株Huh7、MHCC97H、HepG2、SMCC7721、HepG2.2.15和PLC,流式细胞术检测肝癌细胞凋亡,CCK-8测定细胞增殖的抑制率,筛选敏感肝癌细胞株;采用实时定量PCR基因芯片,观察索拉非尼作用于敏感细胞株前后MAPK信号通路基因的表达。结果:索拉非尼作用后,流式细胞术的结果显示,凋亡较明显的细胞株为PLC和HepG2.2.15,相对不明显的细胞株为SMCC7721和MHCC97H;CCK-8测定索拉非尼对PLC、HepG2.2.15、Huh7、HepG2、MHCC97H和SMCC7721细胞的IC50值分别为5.25μmol/L、5.30μmol/L、6.80μmol/L、7.01μmol/L、11.7μmol/L和15.0μmol/L。对索拉非尼相对敏感细胞株和不敏感细胞株分别为PLC和SMCC7721。索拉非尼作用敏感细胞株PLC后,MAPK信号通路表达>2.0倍的有2个,≤0.5倍的有6个。结论:PLC为对索拉非尼相对敏感的人肝癌细胞株;索拉非尼主要导致MAPK信号通路中与调控细胞周期和活化转录因子相关的基因表达发生变化。 AIM: To screen a human hepatocellular carcinoma (HCC) cell line that was sensitive to sorafenib and to explore the changes of gene expression profile of MAPK signal pathway in this cell line. METHODS: Human HCC cell lines of Huh7, MHCC97H, HepG2, SMCC7721, HepG2.2.15 and PLC were selected in the study and treated with sorafenib. The apoptotic rate was detected by flow cytometry. The inhibitory effect of sorafenib on cell growth was deter- mined by CCK-8 assay. The changes of gene expression profile of MAPK signal pathway before and after sorafenib treatment in HCC cell lines were measured by real-time gene array. RESULTS: Apoptotic rate was relatively high in PLC and HepG2.2.15 cells, and was relatively low in SMCC7721 and MHCC97H cells. The values of IC50 in PLC, HepG2.2.15, Huh'/, HepG2, MHCC97H and SMCC7721 cells were 5.25 μmoL/L, 5.30 μmoL/L, 6.80 μmol/L, 7.01 μmol/L, 11.7 μmol/L and 15.0 μmol/L, respectively. The sensitive and resistant HCC cell lines were PLC and SMCC7721, respective- ly. After sorafenib treatment in PLC cells, the gene expression profile of MAPK signal pathway showed that 2 genes were up-regulated to more than 2 times and 6 were down-regulated to below 0.5 times. CONCLUSION: PLC is a sensitive cell line to sorafenib. The changes of gene expression profile after sorafenib treatment are mainly involved in the genes related to cell cycle regulation and transcription factor activation.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2013年第1期159-164,共6页 Chinese Journal of Pathophysiology
基金 广东省自然科学基金博士启动资助项目(No.10451008901004816) 希思科-拜耳先灵青年肝癌研究基金资助项目(No.Y-2009-002 No.Y-B2010-032)
关键词 肝肿瘤 索拉非尼 基因表达 Liver neoplasms Sorafenib Gene expression
  • 相关文献

参考文献14

  • 1Abou-Alfa GK,Schwartz L,Ricci S. Phase Ⅱ study of sorafenib in patients with advanced hepatocellular carcinoma[J].Journal of Clinical Oncology,2006,(26):4293-4300.
  • 2Cheng AL,Kang YK,Chen Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase Ⅲ randomised,double-blind,placebo-controlled trial[J].Lancet Oncology,2009,(01):25-34.doi:10.1016/S1470-2045(08)70285-7.
  • 3Llovet JM,Ricci S,Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma[J].New England Journal of Medicine,2008,(04):378-390.
  • 4阚和平,谭永法,周杰.索拉非尼治疗肝移植术后肝癌复发的疗效与肿瘤组织Ki-67表达及微血管密度的关系[J].中国病理生理杂志,2011,27(8):1549-1551. 被引量:8
  • 5Liu L,Cao Y,Chen C. Sorafenib blocks the RAF/MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J].Cancer Research,2006,(24):11851-11858.
  • 6Tai WT,Cheng AL,Shiau CW. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma[J].Journal of Hepatology,2011,(05):1041-1048.
  • 7Chen KF,Chen HL,Tai WT. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells[J].Journal of Pharmacology and Experimental Therapeutics,2011,(01):155-161.
  • 8Liang Y,Li WW,Yang BW. Aryl hydrocarbon receptor nuclear translocator is associated with tumor growth and progression of hepatocellular carcinoma[J].International Journal of Cancer,2012,(08):1745-1754.
  • 9Nakai S,Masaki T,Shiratori Y. Expression of p57KIP2 in hepatocellular carcinoma:relationship between tumor differentiation and patient survival[J].International Journal of Oncology,2002,(04):769-775.
  • 10Huynh H,Ngo VC,Koong HN. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma[J].Journal of Cellular and Molecular Medicine,2009,(8B):2673-2683.

二级参考文献13

  • 1陈新国,钱峰,张力,张庆.检测抗CD34抗体标记的肿瘤微血管密度预测肝癌肝移植术后复发[J].中华器官移植杂志,2006,27(10):615-618. 被引量:7
  • 2刘换新,杨磊,袁怀文,刘梅.CD117、C-erbB-2及Ki-67蛋白在原发性肝细胞性肝癌中的表达及意义[J].肝胆外科杂志,2007,15(3):228-231. 被引量:3
  • 3Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival[ J]. Hepatology, 2001,33(6) :1394 - 1403.
  • 4Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma[ J ]. J Natl Cancer Inst, 2008,100(10) :698'- 711.
  • 5Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and in- duces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 [ J ]. Cancer Res, 2006, 66 ( 24 ) : 11851 - 11858.
  • 6Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in ad- vanced hepatocellular carcinoma [ J ]. N Engl J Med, 2008,359(4) : 378 -390.
  • 7Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia - Pacific region with ad- vanced hepatocellular carcinoma: a phase III randomized double - blind, placebo - controlled trial [ J ]. Lancet Oncol,2009,10(1) : 25 -34.
  • 8Zhang N, Zhong R, Perez - Pinera P, et al. Identification of the angiogenesis signaling domain in pleiotrophin defines a mechanism of the angiogenic switch [ J]. Biochem Biophys Res Commun, 2006,343 (2) : 653 - 658.
  • 9王芳,符立梧.多靶点抗肿瘤新药索拉非尼的研究进展[J].中国药理学通报,2008,24(8):1117-1120. 被引量:24
  • 10李枫,王峰,李军,杨新顺.多吉美联合介入治疗原发性肝癌20例[J].世界华人消化杂志,2010,18(5):517-520. 被引量:13

共引文献7

同被引文献34

  • 1钟向阳,褚忠华,曹铭辉,闵军,赵海燕.多药耐药基因在原发性肝癌的表达及其临床意义[J].中华实验外科杂志,2005,22(9):1064-1065. 被引量:16
  • 2陈孝平,张万广.肝细胞性肝癌实验研究的热点与展望[J].中华实验外科杂志,2006,23(3):264-265. 被引量:19
  • 3Cheng AL,Kang YK,Chen Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase Ⅲ randomised,double-blind,placebo-controlled trial.Lancet Oncol,2009,10:25-34.
  • 4Llovet J M,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med,2008,359:378-390.
  • 5Kelley RK,Venook AP.Sorafenib in hepatocellular carcinoma:separating the hype from the hope.J Clin Oncol,2008,26:5845-5848.
  • 6Boyault S,Rickman DS,de Reynies A,et al.Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.Hepatology,2007,45:42-52.
  • 7Azam F,Koulaouzidis A.Hepatitis B virus and hepatocarcinogenesis.Ann Hepato1,2008,7:125-129.
  • 8Kim YC,Song KS,Yoon G,et al.Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform celts by suppressing HBx-mediated apoptosis.Oncogene,2001,20:16-23.
  • 9Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepato- cellular carcinoma[ J]. N Engl J Med,2008,359(4) :378-390.
  • 10Roberts LR. Sorafenib in liver cancer-just the beginning[ J]- N Engl J Med,2008,359(4) :420422.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部